Physician profile
Spring Cramer
NPI 1902030596
$8,836.22
in general payments reported to CMS, 2019-2025
40 companies · $1,817 in 2025
The $1,817 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,607 · 2022: $1,670 · 2023: $1,679 · 2024: $2,063 · 2025: $1,817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,559.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,858.46 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,408.65 | 2021-2025 | |
| Lilly USA, LLC | $1,037.70 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $758.05 | 2021-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $588.82 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $376.31 | 2023-2025 | |
| Abbott Laboratories | $300.12 | 2021-2025 | Freestyle Libre 3, Id Now Instrument, Freestyle Libre 2 |
| Lundbeck LLC | $289.87 | 2023-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $241.51 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $238.58 | 2022-2025 | |
| Esperion Therapeutics, INC. | $222.77 | 2021-2025 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $173.69 | 2023-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $153.84 | 2022-2025 | |
| Amgen INC. | $135.60 | 2021-2024 | Repatha |
| Janssen Biotech, INC. | $97.38 | 2021-2022 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $85.11 | 2023-2025 | Rexulti, Nuedexta |
| Corcept Therapeutics | $83.14 | 2024-2025 | Korlym |
| Grifols USA, LLC | $73.69 | 2021-2024 | Prolastin-C Liquid |
| Ibsa Pharma INC. | $56.37 | 2025 | Flector, Tirosint, Licart |
| Merck Sharp & Dohme LLC | $52.98 | 2021 | |
| Sanofi-Aventis U.S. LLC | $52.62 | 2021 | |
| Glaxosmithkline, LLC. | $49.69 | 2024 | Shingrix, Arexvy |
| Biogen, INC. | $46.32 | 2021-2022 | |
| Radius Health, INC. | $46.29 | 2021-2022 | |
| Bausch Health US, LLC | $39.16 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $38.49 | 2022 | |
| Optinose US, INC. | $37.90 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $37.31 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.37 | 2021-2024 | Trulance, Xifaxan |
| Vivus LLC | $30.89 | 2023-2024 | Qsymia |
| Takeda Pharmaceuticals U.S.A., INC. | $28.36 | 2021-2025 | Trintellix |
| Ucb, INC. | $21.76 | 2024 | Bimzelx |
| Verrica Pharmaceuticals INC. | $21.03 | 2024 | Ycanth |
| Exact Sciences Corporation | $20.08 | 2025 | The Cologuard Plus Collection Kit |
| Photonicare INC | $18.69 | 2023 | Otosight Middle Ear Scope |
| Acella Pharmaceuticals, LLC | $17.21 | 2025 | NP Thyroid 60 |
| Boston Scientific Corporation | $17.04 | 2024 | Watchman Flx |
| Regeneron Healthcare Solutions, INC. | $15.55 | 2021 | |
| Hikma Pharmaceuticals USA | $15.53 | 2024 | Ryaltris, Kloxxado |
| Dexcom, INC. | $14.29 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Spring Cramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.